Molten Ventures

Molten Ventures is a venture capital firm established in 2006 and located in London, United Kingdom. The company focuses on investing in European businesses across various sectors, including software, telecommunications, electronics, digital health, and cleantech services. Molten Ventures aims to support innovative entrepreneurs who are poised to shape the future, particularly in areas such as commercial services, deep technology, artificial intelligence, and software as a service (SaaS). By concentrating on these dynamic sectors, the firm seeks to foster the growth of transformative companies that are at the forefront of technological advancement.

George Chalmers

VC Investor

Stuart Chapman

Chief Portfolio Officer and Managing Partner

David Cummings

Partner

Martin Davis

CEO

Inga Deakin

Principal

Jonathan Freuchet-Sibilia

Partner

Vishal Gulati

Venture Partner

Rebecca Hill

VC Investor

Nelly Markova

Principal

Richard Marsh

Senior Partner, Venture Capital

Will Turner

Managing Partner

Past deals in Personal Health

Aktiia

Series B in 2025
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

PocDoc

Seed Round in 2024
PocDoc is a digital health platform focused on the monitoring and testing of cardiovascular, metabolic, and renal diseases. The company has developed an innovative solution that combines a smartphone application with a physical test chip, allowing users to conduct a health assessment using just a single drop of blood. This technology measures several key biomarkers to clinical grade, providing real-time analysis of lifestyle diseases. By enabling individuals to gain control over their physical health, PocDoc facilitates the identification of health issues and supports follow-on care pathways.

Aktiia

Series A in 2024
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

IMU Biosciences

Series A in 2024
IMU Biosciences operates an online health diagnostic platform aimed at advancing precision medicine through immune system mapping. The platform provides medical consultancy services, offering blood test profiles that assess various health markers, including testosterone, ApoA, ApoB, estradiol, glucose, cholesterol, PSA, and iron. By enabling customers to access insightful and cost-effective health assessments, IMU empowers individuals to take control of their health and well-being.

Aktiia

Series A in 2021
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Clue

Series B in 2016
Clue is a Berlin-based reproductive health company that specializes in providing personalized health insights to support individuals throughout their reproductive journeys, from their first period to menopause. Founded in 2012, Clue emerged as one of the pioneering femtech companies and now serves millions of users across over 190 countries. The company focuses on empowering individuals through its mobile application, which features a signature Period Tracking function, fertility cycle analysis, symptom tracking, and calendar reminders. Clue also offers additional personalized services through a subscription plan called Clue Plus. Committed to advancing reproductive health, Clue collaborates with universities, researchers, and healthcare professionals to address gaps in health knowledge and support evidence-based practices.

Lifesum

Series B in 2016
Lifesum is a Swedish digital health startup founded in 2013 and headquartered in Stockholm. The company focuses on enhancing individual health and well-being through a fitness application that encourages proper food choices and sustainable eating habits. Its subscription-based app allows users to plan their diets, track meals and calorie intake, and receive dietary tips and feedback. By leveraging applied psychology and technology, Lifesum aims to empower users to develop healthier habits and ultimately lead happier lives. The company has gained recognition for its rapid growth and was noted by Wired UK as one of Stockholm's most promising startups.

Doutíssima

Seed Round in 2014
Doutissima operates a health and well-being online portal in Brazil, focusing on providing real-time medical advice and informative content. Established in 2013, the platform serves the Brazilian public by offering articles and a discussion forum covering topics such as health, psychology, sexuality, nutrition, and fitness. Doutissima aims to educate and assist users in managing their health and wellness, while also promoting beauty and self-care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.